The clinical environment for HIV infected individuals has changed irrevocably with the advent of highly active antiretroviral therapy (HAART). HAART has brought us on the offensive, restoring a sense of hope for doctors and patients both in the developing world, from what can be compared to a reactive strategy to AIDS, balancing prophylactic therapies and handling opportunistic pathogens. It is, however, just "the end of the beginning," to quote Churchill. Traditionally, gene therapy is split into two kinds; those where the effector molecule is a nucleic acid and those where it is a protein. A second classification is one based on the genetic therapy's mode of action. Thus, antisense molecules dependent on DNA and RNA, ribozyme and decoy RNAs, transdominant negative proteins, suicide genes, and immunomodulatory proteins are present. Gene therapy has been a minority interest in HIV infection care to date. In several ways, since the treatment is directed at something that fights back, it is theoretically more of a challenge than the treatment of disorders such as single gene defects. Like other species, the human race has formed to defend itself against many invading pathogens and, given time, particularly in areas of high disease endemicity and low access to current antivirals, such as sub-Saharan Africa, such genetic selection may begin to occur in the relatively near future. Gene therapy may be viewed by the administration of efficient, non-toxic yet, in this case, non-heritable genetic modulators, as a way to replicate this process and speed it up tremendously. Hopefully, genetic antiviral agents and DNA-based vaccines (which cannot be reviewed in this brief article) would turn out to be simple, non-toxic, low-cost, and uncommon therapies available to people worldwide, not only limited to those in the wealthy West. This review tells about the future scope of the new invention towards the field of HIV /AIDS and their medicinal treatment. People who are interested can send their article towards our journal for publication through this https://www.scholarscentral.org/submissions/hiv-aids-research.html